Thomson Reuters Introduces Biologics Module to its Newport Premium Solution
(Thomson Reuters ONE) -
Add-on Module Provides Intelligence on Biologic and Biosimilar Drugs
Philadelphia, PA, London, UK, March 21, 2011 - Thomson Reuters today announced
the launch of the Newport Biologics Module, the most essential source of
competitive intelligence for the rapidly growing market in biologic and
biosimilar drugs.
The development of biological drugs has seen a dramatic increase during the past
five years, with nearly 6,000 clinical trials with a biological intervention
being reported since 2005, according to Thomson Reuters. With this increase
have come new government regulations promoting competition in the sector.
The Newport Biologics Module is a vital addition to the Thomson Reuters Newport
Premium(TM) solution and will allow generic drug companies, biotech firms or
manufacturers of active pharmaceutical ingredients (API) to assess their own
opportunities to enter the biosimilars market or to spot potential competitive
activity.
The module provides unique manufacturing process data covering biologic drugs,
including recombinant proteins, antibodies, factors, and vaccines. Companies
considering pursuing biosimilar opportunities can analyze multiple potential
bio-manufacturing processes for each drug, genetic sequences, process steps,
starting materials, and equipment required, as well as review related patents
and literature.
"Recent legislative changes in the biologics arena have made it a very enticing
market to pharmaceutical companies and generics alike," said Jon Brett-Harris,
executive vice president at Thomson Reuters. "The Newport Biologics Module
enables companies to evaluate this market more comprehensively and identify the
right opportunity more easily."
Built on more than a decade's experience of supplying solutions to meet the
critical business challenges in the highly competitive and global generic and
API markets, Thomson Reuters Newport products are now used by more than 250 of
the world's leading generic companies and API manufacturers operating in 60
countries around the world.
Thomson Reuters Newport Premium(TM) integrates intelligence on more than 40,000
launched products with more than 300,000 brand names containing over 10,000
different active ingredients and over 20,000 corporate groups involved with
manufacturing and marketing dose products of both small molecule and biologic
active ingredients.
For more information on Newport Premium(TM), please visit:
http://thomsonreuters.com/products_services/science/science_products/a-
z/newport_premium_generics
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial, legal, tax and accounting, healthcare and science and media markets,
powered by the world's most trusted news organization. With headquarters in New
York and major operations in London and Eagan, Minnesota, Thomson Reuters
employs 55,000 people and operates in over 100 countries. For more information,
go to www.thomsonreuters.com.
CONTACTS
Paul Sandell
Manager, PR & Communications
Healthcare & Science
+44 (0)207 433 4704
paul.sandell(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1498297]
Unternehmensinformation / Kurzprofil:
Datum: 21.03.2011 - 05:02 Uhr
Sprache: Deutsch
News-ID 52583
Anzahl Zeichen: 4269
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Introduces Biologics Module to its Newport Premium Solution"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
